Hsbc Holdings PLC raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,369,706 shares of the company's stock after acquiring an additional 527,506 shares during the quarter. Hsbc Holdings PLC owned about 0.18% of Kenvue worth $71,853,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC increased its holdings in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after purchasing an additional 500 shares during the period. White Pine Capital LLC lifted its stake in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock valued at $1,165,000 after buying an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its stake in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after purchasing an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its holdings in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Stock Performance
Shares of KVUE stock traded up $0.11 on Monday, hitting $23.12. The company had a trading volume of 12,011,898 shares, compared to its average volume of 17,099,284. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $23.03 and a 200-day moving average price of $22.45. The firm has a market cap of $44.36 billion, a P/E ratio of 43.62, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. Kenvue's dividend payout ratio is presently 154.72%.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the stock. Barclays lowered their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Redburn Atlantic started coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Finally, UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Kenvue presently has a consensus rating of "Hold" and a consensus price target of $24.42.
Check Out Our Latest Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
